HomeNewsBusinessEconomyAs PM Modi centralizes vaccine procurement, FinMin to seek Parliamentary approval for more funds

As PM Modi centralizes vaccine procurement, FinMin to seek Parliamentary approval for more funds

The budgeted vaccination expenditure and any amount further sought through Supplementary Demand for Grants in the upcoming sessions of Parliament should be enough to fund the centre’s expanded vaccination programme, a senior government official said.

June 07, 2021 / 20:38 IST
Story continues below Advertisement
Representational image
Representational image

Central government has spent around Rs 5,000 crore of the Rs 35,000 crore vaccination budget for 2021-22 so far, and will seek Parliamentary approval for further funds only after exhausting most of that budget, Moneycontrol has learnt.

The budgeted vaccination expenditure and any amount further sought through Supplementary Demand for Grants in the upcoming sessions of Parliament should be enough to fund the Centre’s expanded vaccination programme, a senior government official said.

Story continues below Advertisement

On June 7, Prime Minister Narendra Modi, in an address to the nation, said that the central government will make centralised vaccine procurement for 75 percent of vaccine capacities and ensure vaccine supplies to all states, thus bringing the vaccination for 18-44 age group under the centre’s ambit as well.

Private vaccination centres will be allowed to procure vaccine from the remaining 25 percent. The new vaccination policy rules come in effect from June 21. This means that from that day, the centre will distribute doses to the states for the 18-44 age group, instead of the states procuring them directly from vaccine makers.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show